HTML Sitemap
Posts
- Prodrugs for ADHD Treatments: Opportunities & Potential to Fill Unmet Medical Needs
- Patterns of abuse and routes of administration for immediate-release hydrocodone combination products
- Serdexmethylphenidate/d-Methylphenidate Capsules for Children With ADHD: Effects on SKAMP-C Evaluated Over 13 Hours in a Randomized, Double-blind, Placebo-controlled Laboratory Classroom Study
- Mass Balance and Metabolic Pathway Following Oral Administration of [14C]-Serdexmethylphenidate, a Novel Prodrug of d-Methylphenidate
- Dose Proportionality and Effects of Food on the Pharmacokinetics of Single-Entity Serdexmethylphenidate
- Serdexmethylphenidate/d-Methylphenidate Capsules for Children With ADHD: Effects on SKAMP-C Evaluated Over 13 Hours in a Randomized, Double-blind, Placebo-controlled Laboratory Classroom Study
- Steady-State Pharmacokinetics and Relative Bioavailability of Serdexmethylphenidate/d-Methylphenidate, a Treatment for Attention Deficit Hyperactivity Disorder Containing a Novel Prodrug of d-Methylphenidate
- Single-dose Pharmacokinetics of Serdexmethylphenidate/d-Methylphenidate Capsules in Children and Adolescents With ADHD and Healthy Adults: An Evaluation of Age and Body Weight
- Serdexmethylphenidate/d-Methylphenidate Capsules for Children With ADHD: Effects on SKAMP-C and WREMB-R as Evaluated in a Randomized, Double-blind, Placebo-controlled Laboratory Classroom Study
- Patterns of Abuse of Prescription Stimulant Products from the National Addictions Vigilance Intervention Program (NAVIPPRO): 2010-2018
- Effect of Food and Alternative Dosing Methods on the Pharmacokinetics of KP415, an Investigational ADHD Product Containing the Prodrug, Serdexmethylphenidate (SDX)
- Single-dose Pharmacokinetics of KP415, an Investigational Product Containing the Prodrug Serdexmethylphenidate (SDX), in Children and Adolescents with ADHD
- Dose-Proportionality and Steady-State Pharmacokinetics of KP415, an Investigational ADHD Product Containing Serdexmethylphenidate (SDX), a Novel Prodrug of d-Methylphenidate
- Human Abuse Potential of Oral Serdexmethylphenidate (SDX), a Novel Prodrug of d-Methylphenidate, Compared to Focalin® XR and Phentermine in Recreational Stimulant Abusers
- Human Abuse Potential of Intranasal Serdexmethylphenidate (SDX), a Novel Prodrug of d-Methylphenidate, in Recreational Stimulant Abusers
- Assessment of the Intravenous Abuse Potential Of Serdexmethylphenidate (SDX), a Novel, Investigational Prodrug of D-Methylphenidate: Evidence from Nonclinical and Clinical Studies
- Human Abuse Potential of Intravenous Serdexmethylphenidate (SDX), a Novel Prodrug of d-Methylphenidate, in Recreational Stimulant Abusers
- Dose-finding Study of Abuse-Related Effects of Intranasal d-Methylphenidate in Recreational Stimulant Abusers
- Single- and Multiple-dose Pharmacokinetics of KP415, a Novel d-Methylphenidate Product Containing a Prodrug of d-Methylphenidate, in Healthy Volunteers
- Pharmacokinetics and Abuse Potential of KP511, a Novel Prodrug of Hydromorphone, after Intranasal Administration in Recreation Drug Users
- Oral pharmacokinetics of KP511, a prodrug of hydromorphone, relative to hydromorphone in human volunteers
- Pharmacokinetics and Abuse Potential of Benzhydrocodone, A Novel Prodrug of Hydrocodone, After Intranasal Administration in Recreational Drug Users
- Evaluation of the Long-Term Effect of Arimoclomol in NPC
- Association Between NPC Severity Score Domains and Corresponding Items of the Performance-based Scale for the Assessment and Rating of Ataxia (SARA)
- Efficacy and safety of arimoclomol in Niemann-Pick disease type C: Results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial of a novel treatment
- Clinical disease progression and biomarkers in Niemann–Pick disease type C: a prospective cohort study
- Validation of the 5-domain Niemann-Pick type C Clinical Severity Scale
- A Clinical Study with KP1077 in Adults with Idiopathic Hypersomnia
- Serdexmethylphenidate/dexmethylphenidate effects on sleep in children with attention-deficit/hyperactivity disorder
- Cardiovascular (CV) Safety and Pharmacokinetics (PK) of Serdexmethylphenidate (SDX), a Prodrug of d-Methylphenidate (d-MPH) Compared to Ritalin and Ritalin LA in a Single-Dose Crossover Study in Healthy Volunteers
- Real World Data Collection in Niemann-Pick Disease Type C – Data from Expanded Access Program with Arimoclomol
- Evaluation of the Long-Term Effect of Arimoclomol in NPC – 48 Months Data from CT-ORZY-NPC-002
- Arimoclomol in adults with NPC in a real-world setting: Long-term data from an expanded access program in the USA
- A Novel Investigational Treatment for Hypersomnia: Where We Are and Where We Need to Go
- Pharmacokinetics of Morning and Nighttime Doses of KP1077, an Investigational Treatment for Idiopathic Hypersomnia
- Safety and Efficacy of KP1077 in a Phase 2, Double-blind, Randomized Trial in Patients With Idiopathic Hypersomnia
- Efficacy Results from a 12-month Double-blind Randomized Trial of Arimoclomol for Treatment of Niemann Pick Disease Type C – Presenting an Improved 4-Domain NPC Clinical Severity Scale
- Long-term Efficacy and Safety Evaluation of Arimoclomol Treatment in Patients with Niemann Pick Type C – Data from 48 Months Open Label Trial
- Arimoclomol Safety Profile in the Treatment of NPC in a Real-World Setting: Long-Term Data From an Expanded Access Program in the USA
- Arimoclomol for the Treatment of NPC in a Real-World Setting: Long-Term Outcomes from an Expanded Access Program in the USA
- Modeling the pharmacokinetics of phenylbutyrate in fed and fasted states
- Safety and Efficacy of KP1077 in a Phase 2, Placebo-Controlled, Double-Blind, Randomized Withdrawal Study in Patients with Idiopathic Hypersomnia
- Safety and Efficacy of KP1077 in a Phase 2, Placebo-Controlled, Double-Blind, Randomized Withdrawal Study in Patients with Idiopathic Hypersomnia
- Arimoclomol Upregulates Expression of Genes Belonging to the Coordinated Lysosomal Expression and Regulation (CLEAR) Network
- Qualitative Assessment of the Validity and Standardization of the Swallow Domain in the 5-Domain Niemann-Pick disease type C (NPC) Clinical Severity Scale (5DNPCCSS)
- Efficacy Results from A 12-month Double-blind Randomised Trial of Arimoclomol for Treatment of Niemann-Pick Disease Type C – Presenting A Rescored 4-domain NPC Clinical Severity Scale
- Arimoclomol Upregulates Expression of Genes Belonging to the Coordinated Lysosomal Expression and Regulation (CLEAR) Network
- Arimoclomol for the Treatment of Niemann-pick Disease Type C In a Real-world Setting: Long-term Data from an Expanded Access Program in the United States
- Perseverance Is Key for Regulatory Success in Ultra-Rare Diseases – Key Learnings from Arimoclomol’s Regulatory Journey
- Safety of Arimoclomol in a Pediatric Sub-Study of Niemann-pick Disease Type C Patients Aged 6 To <24 Months at Study Enrollment
- Long-term Efficacy and Safety Evaluation of Arimoclomol Treatment in Patients with Niemann-Pick Type C – Data From 48 Months Open Label Trial
- Arimoclomol Safety Profile in the Treatment of Niemann-pick Disease Type C In a Real-world Setting: Long-term Safety Data from an Expanded Access Program in the United States
- Qualitative Assessment of the Validity and Standardization of the Swallow Domain in the 5-domain Niemann-Pick Disease Type C (NPC) Clinical Severity Scale (5DNPCCSS) And Analysis in an NPC Clinical Trial Data Set
- Efficacy Results from a 12-month Double-blind Randomized Trial of Arimoclomol for the Treatment of Niemann-Pick Disease Type C — Presenting a Rescored 4-domain NPC Clinical Severity Scale
- Mechanistic insights into arimoclomol mediated effects on lysosomal function in Niemann-pick type C disease
- Efficacy results from a 12-month double-blind randomized trial of arimoclomol for treatment of Niemann-Pick disease type C (NPC): Presenting a rescored 4-domain NPC Clinical Severity Scale
- Advances in Niemann-Pick Disease Type C Treatment: The Role of Arimoclomol
- Arimoclomol Upregulates Expression of Genes Belonging to the Coordinated Lysosomal Expression and Regulation (CLEAR) Network
- Long-Term Effectiveness and Safety Evaluation of Arimoclomol Treatment in Patients With Niemann-Pick Disease Type C – Data From the Pivotal Study and Open-Label Extension
- Long-term efficacy and safety of arimoclomol in Niemann-Pick disease type C: Final results of the phase 2/3 NPC-002 48-month open-label extension trial
- Arimoclomol Upregulates Expression of Genes Belonging to the Coordinated Lysosomal Expression and Regulation (CLEAR) Network
- Long-Term Efficacy and Safety Evaluation of Arimoclomol Treatment in Patients With Niemann-Pick Disease Type C – Data From a 48-Month Open-Label Trial
- Arimoclomol for the Treatment of Niemann-Pick Disease Type C in a Real-World Setting: Long-Term Outcomes From an Expanded Access Program in the United States
- ADMINISTRATION OF A DUAL-COATED SODIUM PHENYLBUTYRATE (OLPRUVA) SUSPENSION VIA GASTROSTOMY TUBE
- Efficacy results across a 12-month double-blind randomized trial and an open-label extension phase of arimoclomol for treatment of Niemann-Pick disease type C in patients treated with miglustat
- Arimoclomol for the treatment of Niemann-Pick disease type C in a real-world setting: long-term outcomes from an expanded access program in the United States
- Arimoclomol upregulates expression of genes belonging to the coordinated lysosomal expression and regulation (CLEAR) network
- Safety and efficacy of arimoclomol in a pediatric substudy of Niemann-Pick disease type C patients aged 6 to <24 months at study enrollment
- Changing The Course of NPC: Long-term Evidence for Disease Modification in a Heterogenous Population
Pages
Careers
Portfolio Items
- Corey Watton
- Douglas W. Calder
- John B. Bode
- Wendy Dixon, Ph.D.
- Thomas D. Anderson
- Neil F. McFarlane
- Alvin Shih, M.D.
- Timothy Sangiovanni, CPA
- Christopher M. Lauderback, PhD
- Gerald Orehostky
- Tanya Hayden
- Alison Peters
- Rahsaan W. Thompson
- Adrian Quartel, M.D., FFPM
- Joshua Schafer
- R. LaDuane Clifton, MBA, CPA
- Neil F. McFarlane
- Tamara A. (Seymour) Favorito